Salpingo-Oophorectomy — Cost, Top Hospitals & Success Rates | MyMedicPlus

<p>Salpingo-oophorectomy is the surgical removal of one or both fallopian tubes together with the corresponding ovary or ovaries. The term combines the Greek roots <em>salpinx</em> (tube), <em>oophoron</em> (ovary), and <em>ectomy</em> (surgical removal). When one tube and one ovary are removed, the procedure is termed a <em>unilateral salpingo-oophorectomy</em> (USO); removal of both tubes and both ovaries is termed <em>bilateral salpingo-oophorectomy</em> (BSO).</p><p>The procedure is one of the most commonly performed operations in gynaecology. It is indicated across a remarkably wide range of clinical scenarios — from the emergency management of ovarian torsion or ectopic pregnancy, to elective risk-reduction surgery in women with BRCA1 or BRCA2 pathogenic variants, to treatment of endometriosis, tubo-ovarian abscess, benign ovarian tumours, and early-stage ovarian carcinoma.</p><p>The clinical consequences of salpingo-oophorectomy differ profoundly depending on whether the procedure is unilateral or bilateral, whether the woman is pre- or post-menopausal, and the underlying indication. Unilateral oophorectomy in a pre-menopausal woman with a normal contralateral ovary has minimal hormonal impact; the remaining ovary maintains normal steroidogenesis and menstrual cycling. Bilateral oophorectomy in a pre-menopausal woman, by contrast, causes immediate surgical menopause — an abrupt cessation of ovarian oestrogen, progesterone, and androgen production that carries significant consequences for cardiovascular health, bone density, cognitive function, sexual wellbeing, and overall quality of life.</p><p>These implications mean that the decision to perform salpingo-oophorectomy — particularly bilaterally in pre-menopausal women — requires careful, individualised shared decision-making that weighs the clinical indication, the magnitude of benefits, and the full spectrum of risks and long-term consequences. This guide provides the evidence base for those discussions.</p>

<p>Salpingo-oophorectomy is indicated across a wide range of clinical scenarios. The following are the most common and well-established indications in contemporary gynaecological practice.</p><h3>Ovarian Cancer — Staging and Treatment</h3><p>Bilateral salpingo-oophorectomy is a core component of surgical staging and cytoreduction for epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. It is typically performed as part of a comprehensive staging laparotomy that also includes total hysterectomy, omentectomy, pelvic and para-aortic lymph node dissection, and peritoneal biopsies. For apparent early-stage ovarian cancer in women who have completed childbearing, BSO with hysterectomy provides the definitive surgical treatment.</p><h3>Risk-Reducing Surgery (BRCA1 and BRCA2)</h3><p>Women carrying pathogenic variants in BRCA1 have a lifetime risk of ovarian/tubal/peritoneal cancer of 40–60%, and in BRCA2 of 10–25%, compared to a general population risk of approximately 1.4%. Risk-reducing bilateral salpingo-oophorectomy (RRSO) performed between age 35–40 (BRCA1) or 40–45 (BRCA2) reduces the risk of ovarian cancer by approximately 80% and is associated with a 50–60% reduction in all-cause mortality in this population. RRSO is the most effective risk-reduction strategy available for these women and is recommended by all major international guidelines.</p><h3>Endometriosis — Severe or Refractory</h3><p>In women with severe endometriosis who have completed their family and for whom all other medical and surgical treatments have failed, bilateral salpingo-oophorectomy removes the oestrogen-producing ovaries that drive endometrial implant growth and pain, providing effective and durable pain relief in the majority of patients. The procedure is not appropriate as a first-line surgical option for endometriosis but represents a definitive last resort.</p><h3>Ovarian Torsion</h3><p>When an ovary twists on its vascular pedicle, the resulting ischaemia can render the ovary non-viable within hours. At diagnostic laparoscopy, if the ovary is frankly necrotic and cannot be detorsed to viable perfusion, salpingo-oophorectomy on the affected side is the appropriate treatment. If the ovary appears potentially viable after detorsion, conservation is attempted.</p><h3>Tubo-Ovarian Abscess (TOA)</h3><p>Tubo-ovarian abscess — a complex inflammatory mass involving the tube, ovary, and surrounding structures, arising from ascending pelvic infection — that fails to resolve with intravenous antibiotics may require salpingo-oophorectomy to drain and remove the infected tissue. This prevents septic complications including rupture and peritonitis.</p><h3>Benign Adnexal Masses</h3><p>Large ovarian cysts (dermoids, endometriomas, serous cystadenomas), particularly those that are not amenable to cystectomy without destroying the remaining ovarian tissue, may require oophorectomy. In post-menopausal women with complex adnexal masses, salpingo-oophorectomy is preferred over cystectomy because ovarian conservation in this population provides no hormonal benefit and the risk of malignancy requires excision with intact margins.</p>

<p>Patient eligibility for salpingo-oophorectomy is highly context-dependent, driven by the clinical indication, the woman's menopausal status, reproductive wishes, and overall health.</p><h3>Menopausal Status</h3><p>Pre-menopausal women undergoing bilateral oophorectomy experience immediate surgical menopause with potentially severe short-term symptoms (hot flushes, night sweats, mood disturbance, vaginal dryness) and significant long-term health consequences (accelerated cardiovascular risk, bone loss, cognitive effects). Post-menopausal women tolerate bilateral oophorectomy with fewer hormonal consequences because their ovaries already contribute minimally to circulating oestrogen.</p><h3>Reproductive Status and Future Fertility Desires</h3><p>Bilateral oophorectomy renders a woman permanently infertile; it is therefore not undertaken lightly in women who have not completed their family, unless the clinical indication is urgent or life-threatening. In such women, egg or embryo cryopreservation before surgery should be discussed. Unilateral salpingo-oophorectomy preserves fertility potential through the remaining ovary and tube.</p><h3>Genetic Risk Assessment</h3><p>For risk-reducing surgery, eligibility requires confirmed pathogenic BRCA1 or BRCA2 variant (or other high-penetrance gene such as RAD51C/D or BRIP1) identified by accredited genetic testing, ideally following genetic counselling. The timing of RRSO is individualised: too early results in prolonged surgical menopause; too late reduces the preventive window for cancer.</p><h3>Cardiovascular and Anaesthetic Risk</h3><p>Most salpingo-oophorectomy procedures are performed under general anaesthesia. Standard pre-operative cardiovascular, respiratory, and metabolic assessment is required, particularly for elective procedures. Women with significant comorbidities may require pre-operative optimisation (e.g., blood pressure control, glycaemic management, anaemia correction) before elective surgery.</p><h3>Thromboprophylaxis Requirements</h3><p>Pelvic surgery and the Trendelenburg position used in laparoscopy increase the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE). All patients should be assessed for VTE risk using validated tools (e.g., Caprini score), and appropriate mechanical (compression stockings, pneumatic calf compression) and pharmacological (low-molecular-weight heparin) prophylaxis prescribed.</p>

<p>The surgical approach to salpingo-oophorectomy has evolved substantially over the past three decades, with minimally invasive techniques now the preferred standard in elective cases.</p><h3>Laparoscopic Salpingo-Oophorectomy — Minimally Invasive Standard of Care</h3><p>Under general anaesthesia, three or four small port incisions (5–12 mm) are placed in the abdomen. After establishing pneumoperitoneum with CO2, the pelvis is inspected. The infundibulopelvic (IP) ligament — containing the ovarian artery and vein — is carefully identified, with the ureter visualised beneath it to prevent injury. The IP ligament and utero-ovarian ligament are desiccated and divided using an energy device (bipolar electrosurgery, LigaSure, or Harmonic scalpel). The ovary and tube are freed from surrounding attachments, placed in a specimen retrieval bag, and removed intact through one of the port sites. The procedure typically takes 45–90 minutes.</p><h3>Robotic-Assisted Laparoscopic Salpingo-Oophorectomy</h3><p>Robotic platforms (da Vinci Surgical System) provide superior instrument articulation, a magnified 3D operative field, and tremor filtration. They are particularly advantageous in complex cases — such as dense endometriotic adhesions, a large frozen pelvis, or when simultaneous complex reconstructive procedures are performed. Robotic salpingo-oophorectomy produces equivalent oncological and surgical outcomes to standard laparoscopy but at higher equipment cost.</p><h3>Open (Abdominal) Salpingo-Oophorectomy — Laparotomy</h3><p>A Pfannenstiel (bikini-line) or midline vertical abdominal incision provides direct access to the pelvis. Open surgery is indicated when: the patient is haemodynamically unstable; there is a very large adnexal mass that cannot safely be morcellated or retrieved laparoscopically; extensive adhesions prevent safe laparoscopic access; or when salpingo-oophorectomy is performed as part of a comprehensive cancer staging or cytoreductive procedure that requires wide abdominal access.</p><h3>Vaginal Salpingo-Oophorectomy (via Colpotomy)</h3><p>Salpingo-oophorectomy can occasionally be performed vaginally at the time of vaginal hysterectomy, through the vaginal vault. This approach avoids abdominal incisions entirely but is limited to women with mobile adnexa and adequate vaginal access; it is less versatile than laparoscopic or open approaches.</p><h3>Bilateral vs Unilateral Oophorectomy — Decisions Around Ovarian Conservation</h3><p>The decision of whether to remove one or both ovaries is critical and should be made deliberately, not by default. Current evidence, particularly the landmark work of Parker and colleagues and the Nurses Health Study cohort, shows that in women under 50 undergoing hysterectomy for benign disease, bilateral oophorectomy is associated with increased all-cause mortality compared to ovarian conservation, primarily due to cardiovascular events. This finding underscores the principle that bilateral oophorectomy should be performed only when clinically necessary — not routinely at the time of hysterectomy in pre-menopausal women.</p>

<p>The benefits of salpingo-oophorectomy depend on the indication but span cancer prevention, pain relief, infection eradication, and resolution of life-threatening acute pathology.</p><h3>Dramatic Cancer Risk Reduction in BRCA Carriers</h3><p>For women with BRCA1 pathogenic variants, risk-reducing bilateral salpingo-oophorectomy at age 35–40 reduces ovarian cancer risk by approximately 80% and is associated with a 56% reduction in all-cause mortality in published cohort data. The benefit is somewhat smaller but still clinically important for BRCA2 carriers. RRSO also provides a secondary benefit for BRCA1 carriers: a significant reduction in breast cancer risk (approximately 50%) when performed before natural menopause — presumably through reduction in ovarian oestrogen exposure.</p><h3>Definitive Treatment of Symptomatic Ovarian and Tubal Pathology</h3><p>For benign conditions — large dermoid cysts, endometriomas, serous cystadenomas, hydrosalpinx — salpingo-oophorectomy provides definitive anatomical resolution of the pathology with an extremely low risk of recurrence, unlike cyst aspiration or cystectomy which carry recurrence rates of 20–40%.</p><h3>Pain Relief in Refractory Endometriosis</h3><p>In women with endometriosis that has failed multiple surgical and medical treatments, bilateral oophorectomy removes the principal hormonal driver of endometriotic implant activity. Long-term studies show that 80–90% of women experience significant durable pain relief following bilateral oophorectomy for endometriosis, provided oestrogen replacement (if used) is kept to the minimum effective dose.</p><h3>Ovarian Torsion and Abscess: Life and Limb Preservation</h3><p>In acute settings — ovarian torsion with necrosis, or ruptured tubo-ovarian abscess with sepsis — salpingo-oophorectomy removes the source of ischaemic tissue or infection, preventing septicaemia, peritonitis, and, ultimately, death.</p><h3>Psychological Benefit of Risk Reduction</h3><p>Many women who carry BRCA variants describe persistent, debilitating cancer anxiety that significantly impairs their quality of life before undergoing risk-reducing surgery. Post-RRSO, the vast majority report substantial relief from cancer-related anxiety, improved psychological wellbeing, and a sense of empowerment from having taken proactive control of their health — even when managing the symptoms of surgical menopause.</p>

<p>The risks of salpingo-oophorectomy fall into two categories: acute surgical and anaesthetic risks, and long-term hormonal consequences — the latter being the dominant concern for pre-menopausal women undergoing bilateral surgery.</p><h3>Acute Surgical Complications</h3><p>Standard laparoscopic or open gynaecological surgery risks include: haemorrhage requiring blood transfusion (less than 1% for elective laparoscopy); injury to adjacent structures including the ureter (0.1–0.5%), bladder (0.3–1%), or bowel (0.3–0.5%); port-site or wound infection; incisional hernia at trocar sites; anaesthetic adverse events; and deep vein thrombosis or pulmonary embolism (mitigated by thromboprophylaxis). Conversion from laparoscopic to open surgery occurs in 2–5% of elective cases.</p><h3>Immediate Surgical Menopause (Bilateral Oophorectomy in Pre-Menopausal Women)</h3><p>The most clinically significant consequence of bilateral oophorectomy before natural menopause is the abrupt cessation of ovarian hormone production. Unlike natural menopause, which involves a gradual decline in oestrogen over several years, surgical menopause is immediate and total. Vasomotor symptoms (hot flushes and night sweats) are typically more severe after surgical than after natural menopause, affecting more than 90% of women and often requiring treatment with menopausal hormone therapy (MHT) or non-hormonal alternatives.</p><h3>Accelerated Cardiovascular Risk</h3><p>Oestrogen exerts cardioprotective effects on the vascular endothelium, lipid profile, and insulin sensitivity. Bilateral oophorectomy before age 50 is associated with a significantly increased risk of cardiovascular disease, stroke, and cardiac mortality compared to women who preserve their ovaries or undergo natural menopause. This risk is substantially mitigated by initiation of MHT at the time of surgery and continued until the average age of natural menopause (~51 years).</p><h3>Accelerated Bone Loss — Osteoporosis</h3><p>Oestrogen deficiency dramatically accelerates bone mineral density (BMD) loss; pre-menopausal women typically lose 2–3% BMD per year in the years immediately following bilateral oophorectomy without MHT, compared to 0.5–1% per year in natural menopause. This accelerated loss translates into substantially elevated lifetime fracture risk if left untreated. Baseline dual-energy X-ray absorptiometry (DEXA) scanning before surgery, with repeat scanning at 2–3 years, is recommended for monitoring and guiding intervention.</p><h3>Cognitive Effects and Dementia Risk</h3><p>Observational studies suggest that bilateral oophorectomy before age 50 is associated with an increased risk of cognitive impairment and dementia in later life, particularly when MHT is not used. The neuroprotective role of oestrogen is biologically plausible; its abrupt withdrawal may accelerate age-related neurodegeneration. These findings reinforce the recommendation for MHT use after RRSO in pre-menopausal women.</p><h3>Sexual Dysfunction</h3><p>Surgical menopause commonly causes genitourinary syndrome of menopause (GSM) — vaginal dryness, dyspareunia, urinary urgency — that significantly impairs sexual function and intimate relationships. Ovarian androgen production is also eliminated by bilateral oophorectomy, potentially further reducing libido. Vaginal oestrogen, systemic MHT, and androgen replacement (where appropriate) address these symptoms effectively.</p>

<p>Recovery from salpingo-oophorectomy involves both physical healing and, for women undergoing bilateral oophorectomy, proactive hormonal management to mitigate long-term health consequences.</p><h3>Immediate Post-Operative Recovery</h3><p>After laparoscopic salpingo-oophorectomy most women are discharged home within 24–48 hours. Pain is typically well-managed with oral analgesics. Abdominal distension from residual CO2 gas resolves within 24–48 hours. Shoulder-tip pain — referred from diaphragmatic irritation by CO2 — is common and resolves spontaneously within 48 hours. Women are advised to avoid heavy lifting (over 5 kg), strenuous exercise, and sexual activity for 4–6 weeks.</p><h3>Menopausal Hormone Therapy After Bilateral Oophorectomy</h3><p>For pre-menopausal women undergoing bilateral oophorectomy for benign indications or risk reduction (not oestrogen-sensitive cancer), immediate commencement of MHT is strongly recommended by all major gynaecological and endocrinological societies. Oestrogen-only MHT (in women who have also had a hysterectomy) or combined oestrogen-progestogen MHT (in women with an intact uterus) should be continued until the natural age of menopause (~51 years), after which the risks and benefits of continuation are re-evaluated. Women with BRCA2 variants can safely use MHT after RRSO; for BRCA1 carriers the evidence suggests MHT does not negate the ovarian cancer risk-reduction benefit.</p><h3>Bone Health Monitoring</h3><p>Baseline DEXA scan should be performed before or shortly after bilateral oophorectomy in pre-menopausal women. Repeat DEXA at 2–3 yearly intervals allows monitoring of bone mineral density and guides decisions about initiating or intensifying bone protective therapy. Calcium (1,000 mg/day) and vitamin D (800–1,000 IU/day) supplementation is recommended for all women with surgical menopause.</p><h3>Cardiovascular Surveillance</h3><p>Annual cardiovascular risk assessment — including blood pressure, lipid profile, fasting glucose, and body mass index — should be performed in women who have undergone pre-menopausal bilateral oophorectomy. Lifestyle interventions (smoking cessation, regular aerobic exercise, healthy diet) are particularly important for cardiovascular protection in this group.</p><h3>Cancer Surveillance After Risk-Reducing Surgery</h3><p>RRSO does not eliminate the risk of primary peritoneal carcinoma — a cancer that arises from the peritoneal lining rather than the ovarian surface — which occurs in approximately 1–5% of BRCA1 carriers after RRSO. No effective post-RRSO screening test currently exists for peritoneal cancer, but regular oncological follow-up and awareness of symptoms (bloating, altered bowel habit, pelvic pain) is important.</p>

<p>The cost of salpingo-oophorectomy varies considerably by country, healthcare system, surgical approach, and clinical indication. Understanding cost drivers helps patients make informed decisions about their care pathway.</p><h3>Surgical Approach</h3><p>Laparoscopic salpingo-oophorectomy, while requiring more expensive disposable equipment, results in significantly shorter hospital stays and faster return to work compared to open surgery. Health economic analyses consistently show that laparoscopic surgery is cost-effective compared to open laparotomy for most elective indications. Robotic surgery adds equipment and maintenance costs (USD 1,500–3,500 per case above standard laparoscopy) without evidence of superior clinical outcomes in most straightforward cases.</p><h3>Unilateral vs Bilateral</h3><p>Bilateral salpingo-oophorectomy takes longer (typically 30–60 minutes more than unilateral) and uses additional supplies, resulting in modestly higher procedure costs. In the context of RRSO, bilateral salpingo-oophorectomy also avoids the need for long-term ovarian cancer screening surveillance (annual CA-125 and transvaginal ultrasound), which carries its own cumulative cost.</p><h3>Country-Specific Costs</h3><p>In the United States, total out-of-pocket costs for elective laparoscopic bilateral salpingo-oophorectomy in a private hospital setting typically range from USD 7,000–20,000, inclusive of surgeon, assistant, anaesthesia, and facility fees, depending on geographic location and hospital type. In the UK and Canada, the procedure is provided free under the national health system for clinically appropriate indications. In India, Thailand, Mexico, and Turkey, high-quality elective laparoscopic salpingo-oophorectomy is available for USD 1,500–5,000.</p><h3>Ongoing Costs — MHT and Monitoring</h3><p>For pre-menopausal women undergoing bilateral oophorectomy, the long-term cost of menopausal hormone therapy (typically USD 30–200 per month depending on formulation and country) must be factored into the total lifetime cost of the intervention. DEXA scanning (USD 100–300 per scan), annual cardiovascular risk assessment, and, in BRCA carriers, specialist oncology follow-up contribute additional recurring costs.</p><h3>Genetic Testing and Counselling Costs</h3><p>For women seeking RRSO on genetic grounds, the pathway includes genetic counselling and BRCA sequencing (USD 300–3,000 in the private sector; frequently covered by public health systems for defined high-risk individuals). The cost of genetic testing is a one-time investment that informs cancer risk management across the woman's entire lifespan.</p>

<p>Depending on the clinical indication, several alternatives to salpingo-oophorectomy exist, ranging from intensified surveillance to hormonal suppression to ovarian-conserving surgical approaches.</p><h3>Ovarian Cancer Surveillance (for High-Risk Women Deferring RRSO)</h3><p>Women with BRCA variants who wish to defer risk-reducing surgery — for example to complete their family first — can undergo structured surveillance involving 6-monthly transvaginal ultrasound and serum CA-125. However, it is critical to understand that no current surveillance protocol has been shown to reliably detect ovarian cancer at an early, curable stage. The UKFOCSS trial and other large prospective studies demonstrated that surveillance does not reduce ovarian cancer mortality in BRCA carriers with the reliability of RRSO. Surveillance is therefore a temporising, not equivalent, alternative.</p><h3>Ovarian Cystectomy (for Benign Ovarian Cysts)</h3><p>When the ovarian cyst or mass is benign and the remaining ovarian tissue is healthy, cystectomy — removing only the cyst while preserving the ovarian cortex — is preferable to oophorectomy, particularly in pre-menopausal women wishing to preserve ovarian reserve. Recurrence rates vary by cyst type: endometriomas recur in 20–30% of cases after cystectomy, dermoids in 5–10%.</p><h3>Hormonal Therapy for Endometriosis</h3><p>Medical management of endometriosis — including the combined oral contraceptive pill, progestogen-only therapy, GnRH agonist analogues (with add-back hormone therapy), or the levonorgestrel IUS — provides symptom control and disease suppression without the permanent, irreversible consequences of bilateral oophorectomy. These approaches are appropriate for younger women who have not yet completed their family or for whom the risks of surgical menopause outweigh the benefits of surgery.</p><h3>Laparoscopic Detorsion Without Oophorectomy (for Ovarian Torsion)</h3><p>In ovarian torsion, if the ovary appears potentially viable after laparoscopic untwisting (detorsion), the ovary can be conserved. Multiple studies have demonstrated that even an apparently necrotic-looking ovary may recover viable function after detorsion, making conservation worthwhile in most pre-menopausal women. Routine oophorectomy without attempting detorsion is no longer considered appropriate management.</p><h3>Antibiotics Alone for Tubo-Ovarian Abscess</h3><p>Many tubo-ovarian abscesses respond to intravenous broad-spectrum antibiotics alone (e.g., clindamycin plus gentamicin, or a carbapenem for complex cases) without requiring surgery. Failure to respond within 48–72 hours of antibiotic therapy, or development of clinical signs of rupture or systemic sepsis, triggers surgical intervention. Percutaneous or transvaginal image-guided aspiration is an increasingly used minimally invasive option that may avoid formal salpingo-oophorectomy in selected cases.</p>